Denali Therapeutics elects three Class II directors at 2022 annual meeting

Denali Therapeutics Inc.

Vicki Sato (65.5M for, 15.5M withheld), Erik Harris (80.6M for, 0.3M withheld), and Peter Klein (67.3M for, 13.6M withheld) elected as Class II directors.
Ratification of Ernst & Young as independent auditor for FY2022 passed with 86.8M for, 16K against, 37K abstain.
Non-binding advisory vote on executive compensation approved with 75.8M for, 4.5M against, 0.6M abstain.
70.70% of outstanding shares (86.9M of 122.9M) represented at the meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.